Special Issue "Antibody-Based Imaging and Targeted Therapy in Cancer"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 30 November 2023 | Viewed by 135

Special Issue Editor

Department of Radiotheranostics, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan
Interests: radiopharmaceutical sciences; radionuclide therapy; theranostics; photoimmunotherapy

Special Issue Information

Dear Colleagues,

Antibody-based drugs have shown great potential for cancer imaging and therapy since monoclonal antibodies (mAbs) can selectively deliver substances, such as a radionuclide, dyes, and a toxic molecule to the target. Molecular imaging combines imaging agents with mAbs to specifically image diseased sites in the body. For cancer treatment, cytotoxic payload is conjugated to mAbs to selectively deliver the toxic molecule to cancer cells. Radiolabeled antibody and antibody–drug conjugates (ADCs) consisting of a toxic molecule conjugated to a mAb have been developed and used in clinical practice. Recently, antibody-photoactivating chemical conjugates have been developed as a drug for photoimmunotherapy (PIT). PIT targeting EGFR was approved for clinical use in Japan in 2020.

The development of new antibody-based drugs will make them more useful in cancer treatment. In addition, it is also important to improve the therapeutic effect and/or side effects of drugs by adding modifications or inserting functional linkers.

This Special Issue welcomes research articles and review papers focused on the broad area of development of antibody-based drugs. Research areas may include (but are not limited to) the following: development of new drugs for antibody-based cancer imaging, radioimmunotherapy, ADC, photoimmunotherapy, and novel strategies to improve the therapeutic and/or side effect.

Prof. Dr. Hirofumi Hanaoka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • antibody-based cancer imaging
  • radioimmunotherapy
  • antibody–drug conjugate (ADC)
  • photoimmunotherapy
  • drug delivery system
  • functional linker

Published Papers

This special issue is now open for submission.
Back to TopTop